Boehringer Ingelheim recently announced that it welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline, as it suggests the use of OFEV (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF). This recommendation directed to clinicians is considered…
Researchers at University of Alabama at Birmingham (UAB) recently published in the Journal of Thoracic Disease, a review article on the role played by specific mesothelial cells in the pleura (the membranes surrounding the lungs) in the development of lung disorders like idiopathic pulmonary fibrosis (IPF). The…
Researchers at the Spanish National Cancer Centre (CNIO) and the Complutense University of Madrid in Spain discovered that telomere damage is a cause of idiopathic pulmonary fibrosis (IPF) development. The study was recently published in the journal Cell Reports and is entitled “…
Dr. Dinesh Khanna from the University of Michigan Health System recently presented at the European League Against Rheumatism (EULAR) 2015 Annual European Congress of Rheumatology in Rome new positive safety data regarding ESBRIET for the treatment of interstitial lung disease (ILD). ILD is a group of disorders that cause progressive…
A new study recently published in the journal PLoS One reported data on a specific imaging tool to assess disease progression in patients with idiopathic pulmonary fibrosis (IPF). The study was conducted by an international research team and is entitled “Visual vs Fully Automatic…
A study recently published in the journal PloS One revealed that patients with acute exacerbations of idiopathic pulmonary fibrosis (IPF) may benefit from treatments similar to the ones employed in autoimmune diseases. The study is entitled “Autoantibody-Targeted Tratments for Acute Exacerbations of Idiopathic Pulmonary…
Researchers at the University of Georgia and the Georgia Regents University discovered that the drug triciribine can halt the progression of fatal respiratory diseases like pulmonary fibrosis and pulmonary hypertension. The study was recently published in the British Journal of Pharmacology and is entitled “…
The Medical Advisory Board of the Pulmonary Fibrosis Foundation (PFF)Â recently released an announcement regarding therapies based on stem cells for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a progressive, fatal lung disease in which the alveoli and the lung tissue are damaged, becoming thick and scarred…
Researchers at the Medical School of Nanjing University in China recently published in the journal Respirology findings that reveal how shorter telomeres in chromosomes are associated with a poor survival in patients with idiopathic pulmonary fibrosis (IPF). The study is entitled “Association between telomere…
Clinical stage biotech company Promedior Inc. will present data from its ongoing phase 2 clinical trial of their lead investigational therapy candidate for myelofibrosis at the 20th Congress of the European Hematology Association (EHA) taking place between June 1st and 14th in Vienna, Austria. The presentation on PRM-151, which is also being…
Get regular updates to your inbox.
